ORIENTBIO Fails to Comply with Most Corporate Governance Core Indicators... Exposes Shareholder Return Deficiency and Governance Risks, Promises Future Improvements
Corporate Governance Report Filed: ORIENTBIO submitted its governance report as of May 29, 2026, admitting non-compliance with most key indicators (e.g., 4-week advance notice of shareholder meeting, dividend policy disclosure, CEO succession plan, internal control policy, audit committee).
No Shareholder Return Policy: No dividends for the past 3 fiscal years, no treasury share purchases or cancellations. No formal mid-to-long-term shareholder return policy, resulting in zero dividend predictability. No separate communication events for minority shareholders.
Weak Board Independence and Expertise: Only 1 outside director out of 4 total (25%), no board committees (audit, compensation, nomination). No cumulative voting, chairperson not an outside director. No individual evaluation or compensation policy for outside directors.
Limited Audit Function: Single full-time auditor system, no audit committee (not mandatory as assets under 2 trillion KRW). No dedicated internal audit support organization. No quarterly separate meetings with external auditors without management presence.
Related Party Transaction and Collateral Risks: Loan balance to related parties (e.g., Orient) of 8.495 billion KRW, collateral provided of 5.797 billion KRW (time deposits). Allowance for doubtful accounts on related party receivables: 3.486 billion KRW. No internal transaction pre-review committee.
Inadequate Shareholder Meeting Practices: The 68th regular general meeting (June 27, 2025) was convened only 2 weeks in advance (failed 4-week rule). The extraordinary meeting (May 7, 2026) improved with 37-day notice. No written voting.
Deteriorating Financial Performance: Consolidated revenue increased to 29.397 billion KRW (from 28.005 billion KRW previous year), but operating loss of 3.076 billion KRW and net loss of 13.194 billion KRW, continuing losses. Separate total assets: 84.781 billion KRW.
Deficient Risk Management: No enterprise-wide risk management policy, no compliance program, no formalized internal control manual. Only internal accounting management system and disclosure information management regulations are in place.
Others: Board approved treasury share disposal on Dec 2, 2025 (specific quantity undisclosed). Share consolidation resolution on Mar 31, 2026 (expected change in outstanding shares). No D&O insurance.
[AI Summary]ORIENTBIO's failure to comply with most corporate governance core indicators reveals serious deficiencies in shareholder protection and management transparency; especially the no-dividend policy and related party transactions heighten concerns over minority shareholder value erosion. While the company promises future improvements, the lack of specific implementation timelines and performance metrics limits credibility, and governance risks are expected to weigh on near-term share price.